157 related articles for article (PubMed ID: 37245544)
1. Effectiveness of mRNA and inactivated COVID-19 vaccines: A test-negative study in an infection-naïve Hong Kong population.
Ng RWY; Sze RKH; Chong KC; Zhao S; Ling L; Lui G; Leung ASY; Yeung ACM; Ho WCS; Wong MCS; Chen Z; Boon SS; Hui DSC; Chan PKS
J Infect; 2023 Aug; 87(2):136-143. PubMed ID: 37245544
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM
Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506
[TBL] [Abstract][Full Text] [Related]
3. Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 omicron infection and related hospital admission among people with substance use disorder in Hong Kong: a matched case-control study.
Huang C; Wei Y; Yan VKC; Ye X; Kang W; Yiu HHE; Shami JJP; Cowling BJ; Tse ML; Castle DJ; Chui CSL; Lai FTT; Li X; Wan EYF; Wong CKH; Hayes JF; Chang WC; Chung AKK; Lau CS; Wong ICK; Chan EW
Lancet Psychiatry; 2023 Jun; 10(6):403-413. PubMed ID: 37141907
[TBL] [Abstract][Full Text] [Related]
4. Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study.
McMenamin ME; Nealon J; Lin Y; Wong JY; Cheung JK; Lau EHY; Wu P; Leung GM; Cowling BJ
Lancet Infect Dis; 2022 Oct; 22(10):1435-1443. PubMed ID: 35850128
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of BNT162b2 and Sinovac vaccines against the transmission of SARS-CoV-2 during Omicron-predominance in Hong Kong: A retrospective cohort study of COVID-19 cases.
Zhao S; Guo Z; Sun S; Hung CT; Leung EYM; Wei Y; Wang H; Li K; Yam CHK; Chow TY; Gao J; Jia KM; Chong KC; Yeoh EK
J Clin Virol; 2023 Sep; 166():105547. PubMed ID: 37453162
[TBL] [Abstract][Full Text] [Related]
6. Omicron BA.1-specific T-cell responses in adults vaccinated with CoronaVac or BNT162b2 in Hong Kong: an observational cohort study.
Mok CKP; Chen C; Zhao S; Sun Y; Yiu K; Chan TO; Lai HL; Lai KC; Lau KM; Ling KC; Chan KKP; Ng SS; Ko FW; Peiris M; Hui DS
Lancet Microbe; 2023 Jun; 4(6):e418-e430. PubMed ID: 37086735
[TBL] [Abstract][Full Text] [Related]
7. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
Wong CKH; Lau KTK; Xiong X; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Chan EWY; Gao L; Cheng FWT; Tang SCW; Wong ICK
PLoS Med; 2022 Jun; 19(6):e1004018. PubMed ID: 35727759
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of CoronaVac and BNT162b2 Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.2 Infections in Hong Kong.
Yang B; Wong IOL; Xiao J; Tsang TK; Liao Q; Cowling BJ
J Infect Dis; 2022 Oct; 226(8):1382-1384. PubMed ID: 36054016
[TBL] [Abstract][Full Text] [Related]
9. Estimation of Vaccine Effectiveness of CoronaVac and BNT162b2 Against Severe Outcomes Over Time Among Patients With SARS-CoV-2 Omicron.
Wei Y; Jia KM; Zhao S; Hung CT; Mok CKP; Poon PKM; Man Leung EY; Wang MH; Yam CHK; Chow TY; Guo Z; Yeoh EK; Chong KC
JAMA Netw Open; 2023 Feb; 6(2):e2254777. PubMed ID: 36735253
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of BNT162b2 and CoronaVac vaccines in preventing SARS-CoV-2 Omicron infections, hospitalizations, and severe complications in the pediatric population in Hong Kong: a case-control study.
Yan VKC; Cheng FWT; Chui CSL; Lai FTT; Wong CKH; Li X; Wan EYF; Wong JSC; Chan EWY; Wong ICK; Kwan MYW; Ip P
Emerg Microbes Infect; 2023 Dec; 12(1):2185455. PubMed ID: 36852582
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of BNT162b2 and CoronaVac vaccinations against SARS-CoV-2 omicron infection in people aged 60 years or above: a case-control study.
Wan EYF; Mok AHY; Yan VKC; Chan CIY; Wang B; Lai FTT; Chui CSL; Li X; Wong CKH; Lau CS; Wong ICK; Chan EWY
J Travel Med; 2022 Dec; 29(8):. PubMed ID: 36250571
[TBL] [Abstract][Full Text] [Related]
12. Incidence of diabetes following COVID-19 vaccination and SARS-CoV-2 infection in Hong Kong: A population-based cohort study.
Xiong X; Lui DTW; Chung MSH; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Cheng FWT; Cheung CL; Chan EWY; Lee CH; Woo YC; Tan KCB; Wong CKH; Wong ICK
PLoS Med; 2023 Jul; 20(7):e1004274. PubMed ID: 37486927
[TBL] [Abstract][Full Text] [Related]
13. Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study.
Wan EYF; Chui CSL; Lai FTT; Chan EWY; Li X; Yan VKC; Gao L; Yu Q; Lam ICH; Chun RKC; Cowling BJ; Fong WC; Lau AYL; Mok VCT; Chan FLF; Lee CK; Chan LST; Lo D; Lau KK; Hung IFN; Leung GM; Wong ICK
Lancet Infect Dis; 2022 Jan; 22(1):64-72. PubMed ID: 34411532
[TBL] [Abstract][Full Text] [Related]
14. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
[TBL] [Abstract][Full Text] [Related]
15. COVID-19 Mortality and Vaccine Coverage - Hong Kong Special Administrative Region, China, January 6, 2022-March 21, 2022.
Smith DJ; Hakim AJ; Leung GM; Xu W; Schluter WW; Novak RT; Marston B; Hersh BS
MMWR Morb Mortal Wkly Rep; 2022 Apr; 71(15):545-548. PubMed ID: 35421076
[TBL] [Abstract][Full Text] [Related]
16. Autoimmune conditions following mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccination: A descriptive cohort study among 1.1 million vaccinated people in Hong Kong.
Li X; Gao L; Tong X; Chan VKY; Chui CSL; Lai FTT; Wong CKH; Wan EYF; Chan EWY; Lau KK; Lau CS; Wong ICK
J Autoimmun; 2022 Jun; 130():102830. PubMed ID: 35461018
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of BNT162b2 and CoronaVac vaccinations against mortality and severe complications after SARS-CoV-2 Omicron BA.2 infection: a case-control study.
Yan VKC; Wan EYF; Ye X; Mok AHY; Lai FTT; Chui CSL; Li X; Wong CKH; Li PH; Ma T; Qin S; Wong VKC; Tsang TC; Tsui SH; Chui WCM; Cowling BJ; Leung GM; Lau CS; Wong ICK; Chan EWY
Emerg Microbes Infect; 2022 Dec; 11(1):2304-2314. PubMed ID: 35980089
[TBL] [Abstract][Full Text] [Related]
18. Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population.
Lau JJ; Cheng SMS; Leung K; Lee CK; Hachim A; Tsang LCH; Yam KWH; Chaothai S; Kwan KKH; Chai ZYH; Lo THK; Mori M; Wu C; Valkenburg SA; Amarasinghe GK; Lau EHY; Hui DSC; Leung GM; Peiris M; Wu JT
Nat Med; 2023 Feb; 29(2):348-357. PubMed ID: 36652990
[TBL] [Abstract][Full Text] [Related]
19. Safety of Inactivated and mRNA COVID-19 Vaccination Among Patients Treated for Hypothyroidism: A Population-Based Cohort Study.
Xiong X; Wong CKH; Au ICH; Lai FTT; Li X; Wan EYF; Chui CSL; Chan EWY; Cheng FWT; Lau KTK; Lee CH; Woo YC; Lui DTW; Wong ICK
Thyroid; 2022 May; 32(5):505-514. PubMed ID: 35216517
[No Abstract] [Full Text] [Related]
20. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
